The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner
Eric W. Joseph(Cornell University), Neal Rosen(Memorial Sloan Kettering Cancer Center), James Tsai(Plexxikon (United States)), Madhavi Tadi(Memorial Sloan Kettering Cancer Center), Barry S. Taylor(Memorial Sloan Kettering Cancer Center), Agnès Viale(Genomics (United Kingdom)), Gideon Bollag(Chan Zuckerberg Biohub San Francisco), Christine A. Pratilas(Johns Hopkins University), Poulikos I. Poulikakos, Paul B. Chapman(Memorial Sloan Kettering Cancer Center), Weiqing Wang(Memorial Sloan Kettering Cancer Center), Feng Xing(Shanghai Tenth People's Hospital), Ensar Halilovic(Memorial Sloan Kettering Cancer Center), David B. Solit(Memorial Sloan Kettering Cancer Center), Yogindra Persaud(Memorial Sloan Kettering Cancer Center)
Cited by 447
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET
|Nature Medicine|2012|3.7k
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
|New England Journal of Medicine|2010|3.5k
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
OncoKB: A Precision Oncology Knowledge Base
|JCO Precision Oncology|2017|2.7k